Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $560000.0.

  • Viridian Therapeutics, Inc.\DE's Interest Expenses rose 586.01% to $560000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 1510.08%. This contributed to the annual value of $3.0 million for FY2024, which is 6491.61% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Interest Expenses of $560000.0 as of Q3 2025, which was up 586.01% from $514000.0 recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Interest Expenses' 5-year high stood at $1.4 million during Q4 2024, with a 5-year trough of $3000.0 in Q4 2021.
  • Moreover, its 5-year median value for Interest Expenses was $529000.0 (2024), whereas its average is $471666.7.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Interest Expenses tumbled by 9833.33% in 2021 and then soared by 550000.0% in 2022.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Interest Expenses (Quarter) stood at $3000.0 in 2021, then surged by 5500.0% to $168000.0 in 2022, then surged by 445.24% to $916000.0 in 2023, then skyrocketed by 49.13% to $1.4 million in 2024, then plummeted by 59.0% to $560000.0 in 2025.
  • Its Interest Expenses stands at $560000.0 for Q3 2025, versus $514000.0 for Q2 2025 and $586000.0 for Q1 2025.